21 December 2020: Clinical Research
Urinary Liver-Type Fatty Acid-Binding Protein Predicts Residual Renal Function Decline in Patients on Peritoneal Dialysis
Kenta Torigoe 1ABCDEF , Kumiko Muta 1ABCDEF* , Kiyokazu Tsuji 1B , Ayuko Yamashita 1B , Yuki Ota 1B , Mineaki Kitamura 1DE , Hiroshi Mukae 2G , Tomoya Nishino 1ADEGDOI: 10.12659/MSM.928236
Med Sci Monit 2020; 26:e928236
Table 2 Comparison of clinical characteristics between RRF preservation and decline groups.
| RRF preserve (n=17) | RRF decline (n=18) | P value | |
|---|---|---|---|
| Age (y) | 62.5±12.4 | 59.8±13.6 | 0.31 |
| Duration of PD (mo) | 12 (9.5–24.5) | 14 (12–25.5) | 0.33 |
| Sex (Male: Female) | 12: 5 | 8: 10 | 0.18 |
| BMI (kg/m) | 22.6 (19.8–25.4) | 22.7 (20.8–25.5) | 0.95 |
| Systolic BP (mmHg) | 129.4±22.1 | 129.1±22.4 | 0.96 |
| Diastolic BP (mmHg) | 73.2±13.1 | 77.1±17.1 | 0.43 |
| Primary disease causing ESRD (%) | 0.22 | ||
| Chronic glomerulonephritis | 23.5 | 27.8 | |
| Diabetic kidney disease | 17.7 | 11.1 | |
| Nephrosclerosis | 47.1 | 22.2 | |
| Other | 11.8 | 38.9 | |
| Comorbidity | |||
| Diabetes mellitus (%) | 35.3 | 16.7 | 0.26 |
| Charlson Comorbidity Index | 3 (2–4) | 2 (2–3) | 0.35 |
| ARB/ACE-I (%) | 82.4 | 50 | 0.08 |
| CCB (%) | 76.8 | 50 | 0.16 |
| Diuretic (%) | 94.1 | 72.2 | 0.18 |
| Statin (%) | 29.4 | 27.8 | >0.99 |
| CAPD: APD | 12: 5 | 12: 6 | >0.99 |
| Hb (g/dL) | 11.2±1.3 | 11.0±1.6 | 0.95 |
| Alb (g/dL) | 3.2±0.1 | 3.3±0.1 | 0.10 |
| Corrected Ca (mg/dL) | 9.1±0.6 | 9.3 ±0.7 | 0.34 |
| P (mg/dL) | 5.3 (4.7–5.9) | 5.1 (4.2–5.5) | 0.33 |
| Intact PTH (pg/mL) | 167.6 (104.1–194.5) | 161.6 (76.3–293.2) | 0.84 |
| Total cholesterol (mg/dL) | 190.1±34.1 | 189.3±35.2 | 0.88 |
| HbA1c (%) | 5.3 (5.1–6.1) | 5.4 (5.1–5.7) | 0.72 |
| CRP (mg/dL) | 0.06 (0.04–0.17) | 0.05 (0.03–0.23) | 0.88 |
| Urinary volume (mL/day) | 1,400 (725–1,650) | 1,500 (1,260–1,798) | 0.18 |
| Residual GFR (mL/min) | 3.76 (1.90–5.15) | 4.51 (2.62–7.61) | 0.20 |
| Peritoneal Kt/V | 1.15±0.40 | 0.93±0.33 | 0.19 |
| Total Kt/V | 1.79 (1.50–2.01) | 2.13 (1.79–2.52) | 0.06 |
| 4-h D/P Cr | 0.63 (0.59–0.7) | 0.6 (0.55–0.65) | 0.21 |
| nPCR | 0.88±0.16 | 0.87±0.20 | 0.86 |
| Urinary protein (g/d) | 0.36 (0.19–0.48) | 0.60 (0.50–0.87) | 0.01 |
| Urinary protein (g/g Cr) | 0.68 (0.32–1.00) | 1.00 (0.71–1.31) | 0.07 |
| Urinary L-FABP (μg/d) | 61.5 (35.7–96.0) | 111.2 (76.1–188.6) | 0.002 |
| Urinary L-FABP (μg/g Cr) | 162.7±120.6 | 221.2±123.5 | 0.15 |
| Baseline renal Kt/V | 0.77 (0.42–0.90) | 1.17 (0.64–1.87) | |
| Renal Kt/V decline rate (/y) | 0.05 (−0.05–0.17) | 0.48 (0.38–1.21) | |
| Duration of follow-up (mo) | 11.0 (11.0–13.0) | 11.5 (10.8–12.0) | |
| ACE-I – angiotensin converting enzyme inhibitor; Alb – albumin; APD – automated peritoneal dialysis; ARB – angiotensin II receptor blocker; BMI – body mass index; BP – blood pressure; Ca – calcium; CAPD – continuous ambulatory peritoneal dialysis; CCB – calcium channel blocker; Cr – creatinine; CRP – C-reactive protein; D/P – dialysate/plasma creatinine; GFR – glomerular filtration rate; Hb – hemoglobin; nPCR – normalized protein catabolism rate; L-FABP – L-type fatty acid-binding protein; P – phosphorus; PD – peritoneal dialysis; PTH – parathyroid hormone; RRF – residual renal function. A Fisher exact test or Pearson chi-squared test was conducted to compare nominal variables, and a Wilcoxon rank sum test was conducted to compare continuous variables. | |||